B-cell lymphoma 2 and B-lymphocyte antigen CD20 combination (Bcl-2 + CD20)

The combined pathway interaction of Bcl-2 family modulation and CD20-mediated B-cell depletion is a synergistic therapeutic strategy used to treat B-cell malignancies, most notably Chronic Lymphocytic Leukemia (CLL). Bcl-2 is an anti-apoptotic protein that prevents programmed cell death by sequestering pro-apoptotic factors, while CD20 is a surface antigen specific to the B-cell lineage (UniProt P10415, P11836). By combining a Bcl-2 inhibitor like Venetoclax with an anti-CD20 antibody like Rituximab or Obinutuzumab, the treatment simultaneously removes the internal survival signals of the cancer cell and recruits the immune system to destroy it from the outside. This combination has demonstrated superior efficacy in clinical trials, such as MURANO and CLL14, often leading to deep molecular remissions and allowing for fixed-duration treatment schedules (Seymour et al., NEJM 2018; Fischer et al., NEJM 2019). However, the rapid destruction of tumor cells necessitates careful monitoring for Tumor Lysis Syndrome, particularly during the initiation phase of Bcl-2 inhibition.

Other names

Bcl-2 and CD20 dual targetingVenetoclax plus anti-CD20 therapyBcl-2/CD20 synergistic inhibitionVenetoclax-Rituximab combinationVenetoclax-Obinutuzumab combination

This therapeutic approach utilizes a dual-mechanism to eradicate malignant B-cells. First, Bcl-2 inhibitors (e.g., Venetoclax) bind to the BH3-binding groove of the Bcl-2 protein, displacing pro-apoptotic proteins like BIM and BAK, thereby triggering mitochondrial outer membrane permeabilization (MOMP) and subsequent apoptosis (UniProt P10415). Second, anti-CD20 monoclonal antibodies bind to the CD20 epitope on the B-cell surface, recruiting effector cells for antibody-dependent cellular cytotoxicity (ADCC) and activating the complement cascade for complement-dependent cytotoxicity (CDC) (UniProt P11836). The combination is synergistic because Bcl-2 inhibition lowers the threshold for apoptosis, making the cells more susceptible to the cytotoxic stresses induced by the anti-CD20 antibody (Seymour et al., NEJM 2018).